Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.

BMC cancer - 31 Mar 2016

Simonsson Maria, Veerla Srinivas, Markkula Andrea, Rose Carsten, Ingvar Christian, Jernström Helena

Abstract excerpt

BACKGROUND: Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs. METHODS: The ongoing population-based BC-blood study in Lund, Sweden includes women with primary breast cancer....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP1A2

Share to Genetic Association Studies

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 27029552
DOI: 10.1186/s12885-016-2284-3
PMCID: PMC4815192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.PMID 27029552Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.Semantic proximity Read ↗

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.Semantic proximity Read ↗

Unraveling the molecular significance of CYP1A2 (rs762551; c.-9-154 C>A) genetic variant on breast carcinoma susceptibility: Insights from case-control study and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease riskSemantic proximity Read ↗

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.Semantic proximity Read ↗

Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Semantic proximity Read ↗

Association of polymorphisms of CYP1A1 human gene with breast cancer diagnosis and prognosisSemantic proximity Read ↗

Breast Cancer Susceptibility: Meta-Analysis of Cytochrome P450 2C19 (CYP2C19) and Estrogen Receptor-1 (ESR1) Genetic Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.